他汀类药物用于心血管疾病的一级预防——面对PREVENT研究，临床医生该怎么做？ - Suppr

Suppr

超能文献

Statins for Primary Prevention of Cardiovascular Disease-With PREVENT, What's a Clinician to Do?

作者信息

Khan Sadiya S, Lloyd-Jones Donald M

机构信息

Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

出版信息

JAMA. 2024 Sep 24;332(12):961-962. doi: 10.1001/jama.2024.13887.

DOI:10.1001/jama.2024.13887

PMID:39073988

Abstract

摘要

相似文献

Statins for Primary Prevention of Cardiovascular Disease-With PREVENT, What's a Clinician to Do?他汀类药物用于心血管疾病的一级预防——面对PREVENT研究，临床医生该怎么做？

JAMA. 2024 Sep 24;332(12):961-962. doi: 10.1001/jama.2024.13887.

Evolving Approaches for Statins in Primary Prevention: Progress, but Questions Remain.他汀类药物在一级预防中的不断发展的方法：取得了进展，但问题依然存在。

JAMA. 2016 Nov 15;316(19):1981-1983. doi: 10.1001/jama.2016.15094.

Individualized Risk Communication and Outreach for Primary Cardiovascular Disease Prevention in Community Health Centers: Randomized Trial.社区卫生中心原发性心血管疾病预防的个性化风险沟通与推广：随机试验

Circ Cardiovasc Qual Outcomes. 2015 Nov;8(6):560-6. doi: 10.1161/CIRCOUTCOMES.115.001723. Epub 2015 Nov 10.

2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol: Primary Prevention.2018年美国心脏协会/美国心脏病学会多学会血胆固醇管理指南：一级预防

JAMA Cardiol. 2019 May 1;4(5):488-489. doi: 10.1001/jamacardio.2019.0777.

Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.他汀类药物一级预防心血管疾病的证据：更新的临床结果与实际实践之间的差距。

Arch Cardiovasc Dis. 2014 Mar;107(3):188-200. doi: 10.1016/j.acvd.2014.01.011. Epub 2014 Mar 7.

Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomised clinical trial evidence: The Rotterdam Study.基于现有随机临床试验证据评估心血管疾病一级预防中胆固醇治疗指南的差距：鹿特丹研究。

Eur J Prev Cardiol. 2018 Mar;25(4):420-431. doi: 10.1177/2047487317743352. Epub 2017 Nov 24.

High-Quality Statin Trials Support the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines After the HOPE-3 Trial (Heart Outcomes Prevention Evaluation-3): MESA (The Multiethnic Study of Atherosclerosis).在HOPE-3试验（心脏结局预防评估-3）之后，高质量他汀类药物试验支持2013年美国心脏病学会/美国心脏协会胆固醇指南：动脉粥样硬化多民族研究（MESA）。

Circulation. 2017 Nov 7;136(19):1863-1865. doi: 10.1161/CIRCULATIONAHA.117.029381. Epub 2017 Jun 20.

Implications of lower risk thresholds for statin treatment in primary prevention: analysis of CPRD and simulation modelling of annual cholesterol monitoring.他汀类药物在一级预防中较低风险阈值治疗的意义：CPRD分析及年度胆固醇监测的模拟建模

Prev Med. 2015 Jan;70:14-6. doi: 10.1016/j.ypmed.2014.11.004. Epub 2014 Nov 18.

Real-life evaluation of European and American high-risk strategies for primary prevention of cardiovascular disease in patients with first myocardial infarction.欧美针对首次心肌梗死患者心血管疾病一级预防的高危策略的实际评估。

BMJ Open. 2014 Oct 17;4(10):e005991. doi: 10.1136/bmjopen-2014-005991.

The Evolving Landscape of Cardiovascular Risk Assessment.心血管风险评估的发展态势

JAMA. 2024 Sep 24;332(12):967-969. doi: 10.1001/jama.2024.13247.

引用本文的文献

Statin Eligibility According to Atherosclerotic Cardiovascular Disease Risk in the US.美国根据动脉粥样硬化性心血管疾病风险确定的他汀类药物适用情况

JAMA Cardiol. 2025 Aug 20. doi: 10.1001/jamacardio.2025.2725.

External validation and comparison of the AHA-PREVENT and pooled cohort equations for 10-year ASCVD risk prediction in a contemporary US EHR population.美国当代电子健康记录人群中AHA-PREVENT和汇总队列方程用于10年动脉粥样硬化性心血管疾病（ASCVD）风险预测的外部验证及比较

Am Heart J Plus. 2025 Jul 16;57:100579. doi: 10.1016/j.ahjo.2025.100579. eCollection 2025 Sep.

Performance of the American Heart Association's PREVENT risk score for cardiovascular risk prediction in a multiethnic population.美国心脏协会预防风险评分在多民族人群中预测心血管风险的表现。

Nat Med. 2025 Jul 4. doi: 10.1038/s41591-025-03789-2.

AHA PREVENT Equations and Lipoprotein(a) for Cardiovascular Disease Risk : Insights From MESA and the UK Biobank.美国心脏协会预防方程与脂蛋白（a）对心血管疾病风险的评估：来自多族裔动脉粥样硬化研究（MESA）和英国生物银行的见解

JAMA Cardiol. 2025 Jun 4. doi: 10.1001/jamacardio.2025.1603.

Statin-induced risk of diabetes does not reduce cardiovascular benefits in primary prevention: a 6-year propensity-score matched study in a large population.他汀类药物诱发糖尿病的风险并不会降低一级预防中的心血管获益：一项针对大量人群的6年倾向评分匹配研究。

Cardiovasc Diabetol. 2025 May 31;24(1):233. doi: 10.1186/s12933-025-02798-2.

Performance of PREVENT equations for cardiovascular risk prediction in young patients with myocardial infarction: From the MGB YOUNG-MI registry.PREVENT方程在年轻心肌梗死患者心血管风险预测中的性能：来自MGB YOUNG-MI注册研究。

Am J Prev Cardiol. 2025 Apr 12;22:100992. doi: 10.1016/j.ajpc.2025.100992. eCollection 2025 Jun.

Differences in Statin Eligibility With the Use of Predicting Risk of Cardiovascular Disease EVENTs Versus Pooled Cohort Equations in the UK Biobank.在英国生物银行中，使用心血管疾病事件预测风险与合并队列方程时他汀类药物适用情况的差异。

Am J Cardiol. 2025 Apr 15;241:43-51. doi: 10.1016/j.amjcard.2024.12.034. Epub 2025 Jan 3.

Low-Density Lipoprotein Cholesterol, Cardiovascular Risk Factors, and Predicted Risk in Young Adults.低密度脂蛋白胆固醇、心血管危险因素与年轻人的预估风险。

Clin Cardiol. 2024 Sep;47(9):e70009. doi: 10.1002/clc.70009.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验